Overview

Study of EOC317 in Chinese Patients With Advanced Solid Tumors

Status:
Unknown status
Trial end date:
2020-11-29
Target enrollment:
Participant gender:
Summary
This is an open-label, single-arm phase 1, dose escalation study of EOC317 in patients with advanced solid tumors.
Phase:
Phase 1
Details
Lead Sponsor:
EddingPharm Oncology Co., LTD.
Taizhou EOC Pharma Co., Ltd.